On 12 January 2017, orphan designation (EU/3/16/1812) was granted by the European Commission to Biological Consulting Europe Ltd, United Kingdom, for antroquinonol for the treatment of pancreatic cancer.
The sponsorship was transferred to FGK Representative Service GmbH, Germany, in January 2019.
|Disease / condition||
Treatment of pancreatic cancer
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.